Hormone replacement therapy increases the risk of cranial meningioma
Menée au Danemark auprès de femmes âgées de 55 à 84 ans lors d'un diagnostic de cancer, cette étude cas-témoins évalue l'association entre l'utilisation d'un traitement hormonal substitutif de la ménopause et le risque de méningiome, sur la période 2000-2009
We investigated the influence of hormone replacement therapy (HRT) use on the risk of meningioma in a population-based setting. We conducted a nationwide case–control study in Denmark based on population-based administrative and health registries. The study included all female patients aged 55–84years with a first time diagnosis of meningioma during 2000–2009. The cases were matched on birth year with female population controls. Ever use of HRT since 1995 was defined as ⩾2 HRT prescriptions and categorised according to HRT type (oestrogen only, combined oestrogen–progestagen, and progestagen only) and cumulated duration of use (<1, ⩾1 to <5, ⩾5 to <10, ⩾10years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for meningioma associated with HRT use, and adjusting for potential confounders. We identified 924 cases and 6122 controls. Ever use of HRT was associated with an increased risk of meningioma (OR, 1.3; 95%CI, 1.1–1.5) compared with non-use (0–1 prescriptions). The risk increased with increasing duration of HRT use, reaching an OR of 1.7 (95% CI, 1.2–2.3) after more than 10years of use. The risk of meningioma associated with long-term (⩾10years) HRT use was most pronounced for combined oestrogen–progestagen therapy (OR, 2.2; 95% CI, 1.4–3.3), especially when this regimen constituted the sole HRT therapy (OR, 2.7; 95% CI, 0.9–7.5), although the latter estimate was based on small numbers. Long-term HRT use, particularly of combined oestrogen–progestagen therapy, may increase the risk of meningioma.
http://linkinghub.elsevier.com/retrieve/pii/S0959804913004346?showall=true